Disrupting GBP1-IDO-1 interactions with agents like astragaloside IV diminishes immune evasion, enhancing chemo- or immunotherapy efficacy, a mechanism evaluable through immune profiling, tumor growth assays, or patient-derived xenografts [55]. Here, IDO1 is linked to neoplasm.